European Regulator Starts Review of Lyme Vaccine
Valneva shares surged on European markets after the European Medicines Agency accepted for review the vaccine manufacturer’s marketing authorization application for its investigational Lyme disease vaccine. Trading data analyzed by Zonebourse showed the company’s stock climbing 30.3% to reach 3.20 euros around midday, marking the strongest performance on the SBF 120 index. The regulatory acceptance represents a critical milestone for the vaccine candidate, which has been developed through a co-development partnership between Valneva and American pharmaceutical giant Pfizer.
Phase 3 Trials Yield Robust Safety and Efficacy Data
According to ABC Bourse, the regulatory filing is underpinned by robust data from a pivotal Phase 3 clinical trial. The study demonstrated an efficacy rate exceeding 70% in preventing Lyme disease cases among individuals aged five years and older. Valneva reported that the investigational shot was well tolerated throughout the trial phases, with no safety issues identified during the evaluation of safety, tolerability, immunogenicity, and manufacturing consistency across production batches.
Analyst Outlook and Regulatory Risk Reduction
Investment firm Stifel indicated that it anticipates potential regulatory approval for the vaccine during the third quarter of next year, according to market reports. Meanwhile, brokerage Portzamparc highlighted that the European progress validates the strength of the submission package and buoys hopes for parallel advancements in the United States, where discussions between Pfizer and health authorities remain ongoing.
Commercial Milestones and Financial Impact
Under the terms of the collaboration agreement between the two drugmakers, Valneva stands to receive a substantial milestone payment of $143 million, equivalent to approximately €124 million, from Pfizer upon the eventual commercialization of the Lyme disease vaccine.
“The acceptance for review of the marketing authorization application marks a major milestone, while more than 200 million people live in areas at risk of Lyme disease in Europe,” stated Thomas Lingelbach, Chief Executive Officer of Valneva, in an official company release reported by Zonebourse.
Public Health Burden and Disease Transmission
Lyme disease is a vector-borne illness caused by the bacterium Borrelia burgdorferi, which is transmitted to humans through the bites of infected Ixodes ticks. The infection poses a substantial public health challenge across North America and Europe, driving persistent demand for preventive interventions.
Data from the U.S. Centers for Disease Control and Prevention (CDC) cited by ABC Bourse indicate that numerous individuals are diagnosed and treated annually in the United States. In Europe, public health reporting accounts for additional annual cases, underlining the extensive commercial and medical footprint a licensed vaccine could secure across both regions.
As the European Medicines Agency initiates its formal evaluation procedure, market participants and public health officials await further updates regarding the regulatory timeline and potential advisory committee reviews.
Keep reading